Arnon P Kater, EHA 2018 – TP53 Mutations in Relapsed/Refractory CLL – the MURANO Trial
touchONCOLOGY talks to Arnon P Kater from the Academisch Medisch Centrum Universiteit van Amsterdam about the MURANO study and the impact of TP53-mutated clone size on outcome of relapsed/refractory (R/R) CLL patients treated with venetoclax plus rituximab.
1. Why do chronic lymphocytic leukaemia (CLL) patients with alterations in the TP53 pathway represent an unmet clinical need? (0:10)
2. Could you tell us a little about venetoclax and its efficacy in CLL? (1:11)
3. What is the safety profile of venetoclax? (2:05)
4. What was the rationale for the investigation of the impact of clone size on outcomes in patients in the MURANO study? (2:56)
5. What were the findings of this investigation and what are the implications of these findings? (4:29)
Speaker disclosures: Arnon P Kater has nothing to disclose in relation to this video interview.
Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018.
Share this Video
Related Videos In Haematological Malignancies
Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study
The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the ASCEMBL findings, what we […]
Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib
Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the […]
Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!